213 related articles for article (PubMed ID: 36710682)
1. Brain Gray Matter Volume Mediated the Correlation Between Plasma P-Tau and Cognitive Function of Early Alzheimer's Disease in China: A Cross-Sectional Observational Study.
Wan K; Yin W; Tang Y; Zhu W; Wang Z; Zhou X; Zhang W; Zhang C; Yu X; Zhao W; Li C; Zhu X; Sun Z
J Alzheimers Dis; 2023; 92(1):81-93. PubMed ID: 36710682
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
3. Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort.
Chaudhary S; Zhornitsky S; Chao HH; van Dyck CH; Li CR
J Alzheimers Dis; 2022; 85(3):1251-1265. PubMed ID: 34924392
[TBL] [Abstract][Full Text] [Related]
4. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
Saloner R; VandeVrede L; Asken BM; Paolillo EW; Gontrum EQ; Wolf A; Lario-Lago A; Milà-Alomà M; Triana-Baltzer G; Kolb HC; Dubal DB; Rabinovici GD; Miller BL; Boxer AL; Casaletto KB; Kramer JH
Alzheimers Dement; 2024 Jan; 20(1):376-387. PubMed ID: 37639492
[TBL] [Abstract][Full Text] [Related]
5. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.
Murray ME; Moloney CM; Kouri N; Syrjanen JA; Matchett BJ; Rothberg DM; Tranovich JF; Sirmans TNH; Wiste HJ; Boon BDC; Nguyen AT; Reichard RR; Dickson DW; Lowe VJ; Dage JL; Petersen RC; Jack CR; Knopman DS; Vemuri P; Graff-Radford J; Mielke MM
Mol Neurodegener; 2022 Dec; 17(1):85. PubMed ID: 36575455
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
9. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
10. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.
Kimura A; Yoshikura N; Hayashi Y; Inuzuka T
J Alzheimers Dis; 2018; 61(2):581-588. PubMed ID: 29171996
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated tau in Alzheimer's disease.
Telser J; Grossmann K; Wohlwend N; Risch L; Saely CH; Werner P
Adv Clin Chem; 2023; 116():31-111. PubMed ID: 37852722
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.
Mundada NS; Rojas JC; Vandevrede L; Thijssen EH; Iaccarino L; Okoye OC; Shankar R; Soleimani-Meigooni DN; Lago AL; Miller BL; Teunissen CE; Heuer H; Rosen HJ; Dage JL; Jagust WJ; Rabinovici GD; Boxer AL; La Joie R
Alzheimers Res Ther; 2023 Sep; 15(1):157. PubMed ID: 37740209
[TBL] [Abstract][Full Text] [Related]
16. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889
[TBL] [Abstract][Full Text] [Related]
18. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
[TBL] [Abstract][Full Text] [Related]
19. Correlation between parameters related to sarcopenia and gray matter volume in patients with mild to moderate Alzheimer's disease.
Liu S; Zhang Y; Peng B; Pang C; Li M; Zhu J; Liu CF; Hu H
Aging Clin Exp Res; 2022 Dec; 34(12):3041-3053. PubMed ID: 36121640
[TBL] [Abstract][Full Text] [Related]
20. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease.
Dicks E; van der Flier WM; Scheltens P; Barkhof F; Tijms BM;
Neurobiol Aging; 2020 Oct; 94():71-80. PubMed ID: 32585492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
